BioSpace News Archive

The U.S. Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases.

Matica Biotechnology, Inc today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry.

Yuman Fong, M.D., the Sangiacomo Family Chair in Surgical Oncology at City of Hope, a world-renowned cancer research and treatment organization, was presented with one of the highest honors in health and medicine.

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the IND submission for the initiation of phase 2 clinical trial of efineptakin alfa (also known as TJ107/GX-I7/NT-I7) in combination with PD-1 antibody in patients with advanced solid tumors.

Sirnaomics, Inc., announced today that Professor Brian Berman, M.D., Ph.D., Professor Emeritus, Dermatology and Dermatologic Surgery, University of Miami will be giving a talk on the clinical study result of the Company’s lead drug candidate, STP705, at the 2021 Fall Clinical Dermatology Conference.

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced clinical trial results demonstrating the first-ever in vivo genome editing in children.

AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapies, today announced sponsored research to evaluate AB-329, an AXL inhibitor in metastatic breast cancer.

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SMART-Seq® Pro kit for the ICELL8® cx Single-Cell System.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephrology (ASN) Annual Meeting to be held November 4-7, 2021.